Viatris will secure FDA approval for its low-dose estrogen weekly patch, clearing the way for a new contraceptive option in the United States. The company submitted an NDA that the FDA accepted under the 505(b)(2) pathway and the agency set a PDUFA action date of July 30, 2026. The filing was suppo…